APO Research
Talk to an analyst

APO RESEARCH · REPORT

Treatments for Alpha-1

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Treatments for Alpha-1 Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchTreatments for Alpha-1 Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Treatments for Alpha-1 Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Treatments for Alpha-1 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Treatments for Alpha-1 Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Treatments for Alpha-1 Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Treatments for Alpha-1 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Treatments for Alpha-1 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Treatments for Alpha-1 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Treatments for Alpha-1 market include Takeda, Teva Pharmaceutical Industries, Pfizer, GlaxoSmithKline, Baxter, AstraZeneca, Vertex Pharmaceuticals, ProMetic Life Sciences and Kedrion Group, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Treatments for Alpha-1 market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Treatments for Alpha-1 and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Treatments for Alpha-1 revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Treatments for Alpha-1 market.

Treatments for Alpha-1 Segment by Company

Takeda

Teva Pharmaceutical Industries

Pfizer

GlaxoSmithKline

Baxter

AstraZeneca

Vertex Pharmaceuticals

ProMetic Life Sciences

Kedrion Group

Kamada Ltd

Grifols

CSL Behring

Chiesi Pharmaceuticals

Boehringer Ingelheim

Treatments for Alpha-1 Segment by Type

Augmentation Therapy

Diabetes

Cystic Fibrosis(CF)

Non-CF Bronchiectasis(NCFB)

Other

Treatments for Alpha-1 Segment by Application

Hospitals

Specialty Clinics

Pharmacies

Treatments for Alpha-1 Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Treatments for Alpha-1 status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Treatments for Alpha-1 key companies, revenue, market share, and recent developments.

3. To split the Treatments for Alpha-1 breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Treatments for Alpha-1 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Treatments for Alpha-1 significant trends, drivers, influence factors in global and regions.

6. To analyze Treatments for Alpha-1 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treatments for Alpha-1 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Treatments for Alpha-1 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treatments for Alpha-1.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Treatments for Alpha-1 industry.

Chapter 3: Detailed analysis of Treatments for Alpha-1 company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Treatments for Alpha-1 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Treatments for Alpha-1 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Treatments for Alpha-1 Industry Trends Table 2. Treatments for Alpha-1 Industry Drivers Table 3. Treatments for Alpha-1 Industry Opportunities and Challenges Table 4. Treatments for Alpha-1 Industry Restraints Table 5. Global Treatments for Alpha-1 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Treatments for Alpha-1 Revenue Share by Company (2021-2026) Table 7. Global Treatments for Alpha-1 Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Treatments for Alpha-1 Key Company Manufacturing Base & Headquarters Table 9. Global Treatments for Alpha-1 Company, Product Type & Application Table 10. Global Treatments for Alpha-1 Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Treatments for Alpha-1 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Augmentation Therapy Table 15. Significant Companies of Diabetes Table 16. Significant Companies of Cystic Fibrosis(CF) Table 17. Significant Companies of Non-CF Bronchiectasis(NCFB) Table 18. Significant Companies of Other Table 19. Global Treatments for Alpha-1 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Treatments for Alpha-1 Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Treatments for Alpha-1 Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Treatments for Alpha-1 Sales Value Share by Type (2021-2026) Table 23. Global Treatments for Alpha-1 Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals Table 25. Significant Companies of Specialty Clinics Table 26. Significant Companies of Pharmacies Table 27. Global Treatments for Alpha-1 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Treatments for Alpha-1 Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Treatments for Alpha-1 Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Treatments for Alpha-1 Sales Value Share by Application (2021-2026) Table 31. Global Treatments for Alpha-1 Sales Value Share by Application (2027-2032) Table 32. Global Treatments for Alpha-1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Treatments for Alpha-1 Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Treatments for Alpha-1 Sales Value Share by Region (2021-2026) Table 35. Global Treatments for Alpha-1 Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Treatments for Alpha-1 Sales Value Share by Region (2027-2032) Table 37. Global Treatments for Alpha-1 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Treatments for Alpha-1 Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Treatments for Alpha-1 Sales Value Market Share by Country (2021-2026) Table 40. Global Treatments for Alpha-1 Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Treatments for Alpha-1 Sales Value Market Share by Country (2027-2032) Table 42. Takeda Company Information Table 43. Takeda Business Overview Table 44. Takeda Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Takeda Treatments for Alpha-1 Product Portfolio Table 46. Takeda Recent Development Table 47. Teva Pharmaceutical Industries Company Information Table 48. Teva Pharmaceutical Industries Business Overview Table 49. Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio Table 51. Teva Pharmaceutical Industries Recent Development Table 52. Pfizer Company Information Table 53. Pfizer Business Overview Table 54. Pfizer Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Pfizer Treatments for Alpha-1 Product Portfolio Table 56. Pfizer Recent Development Table 57. GlaxoSmithKline Company Information Table 58. GlaxoSmithKline Business Overview Table 59. GlaxoSmithKline Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. GlaxoSmithKline Treatments for Alpha-1 Product Portfolio Table 61. GlaxoSmithKline Recent Development Table 62. Baxter Company Information Table 63. Baxter Business Overview Table 64. Baxter Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Baxter Treatments for Alpha-1 Product Portfolio Table 66. Baxter Recent Development Table 67. AstraZeneca Company Information Table 68. AstraZeneca Business Overview Table 69. AstraZeneca Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. AstraZeneca Treatments for Alpha-1 Product Portfolio Table 71. AstraZeneca Recent Development Table 72. Vertex Pharmaceuticals Company Information Table 73. Vertex Pharmaceuticals Business Overview Table 74. Vertex Pharmaceuticals Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio Table 76. Vertex Pharmaceuticals Recent Development Table 77. ProMetic Life Sciences Company Information Table 78. ProMetic Life Sciences Business Overview Table 79. ProMetic Life Sciences Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio Table 81. ProMetic Life Sciences Recent Development Table 82. Kedrion Group Company Information Table 83. Kedrion Group Business Overview Table 84. Kedrion Group Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Kedrion Group Treatments for Alpha-1 Product Portfolio Table 86. Kedrion Group Recent Development Table 87. Kamada Ltd Company Information Table 88. Kamada Ltd Business Overview Table 89. Kamada Ltd Treatments for Alpha-1 Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Kamada Ltd Treatments for Alpha-1 Product Portfolio Table 91. Kamada Ltd Recent Development Table 92. Grifols Company Information Table 93. Grifols Business Overview Table 94. Grifols Treatments for Alpha-1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Grifols Treatments for Alpha-1 Product Portfolio Table 96. Grifols Recent Development Table 97. CSL Behring Company Information Table 98. CSL Behring Business Overview Table 99. CSL Behring Treatments for Alpha-1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. CSL Behring Treatments for Alpha-1 Product Portfolio Table 101. CSL Behring Recent Development Table 102. Chiesi Pharmaceuticals Company Information Table 103. Chiesi Pharmaceuticals Business Overview Table 104. Chiesi Pharmaceuticals Treatments for Alpha-1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 105. Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio Table 106. Chiesi Pharmaceuticals Recent Development Table 107. Boehringer Ingelheim Company Information Table 108. Boehringer Ingelheim Business Overview Table 109. Boehringer Ingelheim Treatments for Alpha-1 Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 110. Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio Table 111. Boehringer Ingelheim Recent Development Table 112. Research Programs/Design for This Report Table 113. Authors List of This Report Table 114. Secondary Sources Table 115. Primary Sources List of Figures Figure 1. Treatments for Alpha-1 Product Image Figure 2. Global Treatments for Alpha-1 Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Treatments for Alpha-1 Market Size (2021-2032) & (US$ Million) Figure 4. Global Treatments for Alpha-1 Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Augmentation Therapy Image Figure 8. Diabetes Image Figure 9. Cystic Fibrosis(CF) Image Figure 10. Non-CF Bronchiectasis(NCFB) Image Figure 11. Other Image Figure 12. Global Treatments for Alpha-1 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Treatments for Alpha-1 Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Treatments for Alpha-1 Sales Value Share by Type (2021-2032) Figure 15. Hospitals Image Figure 16. Specialty Clinics Image Figure 17. Pharmacies Image Figure 18. Global Treatments for Alpha-1 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Treatments for Alpha-1 Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Treatments for Alpha-1 Sales Value Share by Application (2021-2032) Figure 21. Global Treatments for Alpha-1 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Treatments for Alpha-1 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Treatments for Alpha-1 Sales Value (2021-2032) & (US$ Million) Figure 24. North America Treatments for Alpha-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Treatments for Alpha-1 Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Treatments for Alpha-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Treatments for Alpha-1 Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Treatments for Alpha-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Treatments for Alpha-1 Sales Value (2021-2032) & (US$ Million) Figure 30. South America Treatments for Alpha-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Treatments for Alpha-1 Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Treatments for Alpha-1 Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Treatments for Alpha-1 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Augmentation Therapy
  • Diabetes
  • Cystic Fibrosis(CF)
  • Non-CF Bronchiectasis(NCFB)
  • Other
Applications
  • Hospitals
  • Specialty Clinics
  • Pharmacies
Companies covered
  • Takeda
  • Teva Pharmaceutical Industries
  • Pfizer
  • GlaxoSmithKline
  • Baxter
  • AstraZeneca
  • Vertex Pharmaceuticals
  • ProMetic Life Sciences
  • Kedrion Group
  • Kamada Ltd
  • Grifols
  • CSL Behring
  • Chiesi Pharmaceuticals
  • Boehringer Ingelheim

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Treatments for Alpha-1 Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Treatments for Alpha-1 Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Treatments for Alpha-1 Market Dynamics
  1. 2.1 Treatments for Alpha-1 Industry Trends
  2. 2.2 Treatments for Alpha-1 Industry Drivers
  3. 2.3 Treatments for Alpha-1 Industry Opportunities and Challenges
  4. 2.4 Treatments for Alpha-1 Industry Restraints
3 Treatments for Alpha-1 Market by Company
  1. 3.1 Global Treatments for Alpha-1 Company Revenue Ranking in 2025
  2. 3.2 Global Treatments for Alpha-1 Revenue by Company (2021-2026)
  3. 3.3 Global Treatments for Alpha-1 Company Ranking (2024-2026)
  4. 3.4 Global Treatments for Alpha-1 Company Manufacturing Base and Headquarters
  5. 3.5 Global Treatments for Alpha-1 Company Product Type and Application
  6. 3.6 Global Treatments for Alpha-1 Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Treatments for Alpha-1 Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Treatments for Alpha-1 Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Treatments for Alpha-1 Market by Type
  1. 4.1 Treatments for Alpha-1 Type Introduction
  2. 4.1.1 Augmentation Therapy
  3. 4.1.2 Diabetes
  4. 4.1.3 Cystic Fibrosis(CF)
  5. 4.1.4 Non-CF Bronchiectasis(NCFB)
  6. 4.1.5 Other
  7. 4.2 Global Treatments for Alpha-1 Sales Value by Type
  8. 4.2.1 Global Treatments for Alpha-1 Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Treatments for Alpha-1 Sales Value by Type (2021-2032)
  10. 4.2.3 Global Treatments for Alpha-1 Sales Value Share by Type (2021-2032)
5 Treatments for Alpha-1 Market by Application
  1. 5.1 Treatments for Alpha-1 Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Specialty Clinics
  4. 5.1.3 Pharmacies
  5. 5.2 Global Treatments for Alpha-1 Sales Value by Application
  6. 5.2.1 Global Treatments for Alpha-1 Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Treatments for Alpha-1 Sales Value by Application (2021-2032)
  8. 5.2.3 Global Treatments for Alpha-1 Sales Value Share by Application (2021-2032)
6 Treatments for Alpha-1 Regional Value Analysis
  1. 6.1 Global Treatments for Alpha-1 Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Treatments for Alpha-1 Sales Value by Region (2021-2032)
  3. 6.2.1 Global Treatments for Alpha-1 Sales Value by Region: 2021-2026
  4. 6.2.2 Global Treatments for Alpha-1 Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Treatments for Alpha-1 Sales Value (2021-2032)
  7. 6.3.2 North America Treatments for Alpha-1 Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Treatments for Alpha-1 Sales Value (2021-2032)
  10. 6.4.2 Europe Treatments for Alpha-1 Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Treatments for Alpha-1 Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Treatments for Alpha-1 Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Treatments for Alpha-1 Sales Value (2021-2032)
  16. 6.6.2 South America Treatments for Alpha-1 Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Treatments for Alpha-1 Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Treatments for Alpha-1 Sales Value Share by Country, 2025 VS 2032
7 Treatments for Alpha-1 Country-level Value Analysis
  1. 7.1 Global Treatments for Alpha-1 Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Treatments for Alpha-1 Sales Value by Country (2021-2032)
  3. 7.2.1 Global Treatments for Alpha-1 Sales Value by Country (2021-2026)
  4. 7.2.2 Global Treatments for Alpha-1 Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Treatments for Alpha-1 Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Treatments for Alpha-1 Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Treatments for Alpha-1 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Treatments for Alpha-1 Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva Pharmaceutical Industries
  8. 8.2.1 Teva Pharmaceutical Industries Company Information
  9. 8.2.2 Teva Pharmaceutical Industries Business Overview
  10. 8.2.3 Teva Pharmaceutical Industries Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Pharmaceutical Industries Treatments for Alpha-1 Product Portfolio
  12. 8.2.5 Teva Pharmaceutical Industries Recent Developments
  13. 8.3 Pfizer
  14. 8.3.1 Pfizer Company Information
  15. 8.3.2 Pfizer Business Overview
  16. 8.3.3 Pfizer Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Pfizer Treatments for Alpha-1 Product Portfolio
  18. 8.3.5 Pfizer Recent Developments
  19. 8.4 GlaxoSmithKline
  20. 8.4.1 GlaxoSmithKline Company Information
  21. 8.4.2 GlaxoSmithKline Business Overview
  22. 8.4.3 GlaxoSmithKline Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GlaxoSmithKline Treatments for Alpha-1 Product Portfolio
  24. 8.4.5 GlaxoSmithKline Recent Developments
  25. 8.5 Baxter
  26. 8.5.1 Baxter Company Information
  27. 8.5.2 Baxter Business Overview
  28. 8.5.3 Baxter Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Baxter Treatments for Alpha-1 Product Portfolio
  30. 8.5.5 Baxter Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Treatments for Alpha-1 Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Vertex Pharmaceuticals
  38. 8.7.1 Vertex Pharmaceuticals Company Information
  39. 8.7.2 Vertex Pharmaceuticals Business Overview
  40. 8.7.3 Vertex Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Vertex Pharmaceuticals Treatments for Alpha-1 Product Portfolio
  42. 8.7.5 Vertex Pharmaceuticals Recent Developments
  43. 8.8 ProMetic Life Sciences
  44. 8.8.1 ProMetic Life Sciences Company Information
  45. 8.8.2 ProMetic Life Sciences Business Overview
  46. 8.8.3 ProMetic Life Sciences Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProMetic Life Sciences Treatments for Alpha-1 Product Portfolio
  48. 8.8.5 ProMetic Life Sciences Recent Developments
  49. 8.9 Kedrion Group
  50. 8.9.1 Kedrion Group Company Information
  51. 8.9.2 Kedrion Group Business Overview
  52. 8.9.3 Kedrion Group Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Kedrion Group Treatments for Alpha-1 Product Portfolio
  54. 8.9.5 Kedrion Group Recent Developments
  55. 8.10 Kamada Ltd
  56. 8.10.1 Kamada Ltd Company Information
  57. 8.10.2 Kamada Ltd Business Overview
  58. 8.10.3 Kamada Ltd Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Kamada Ltd Treatments for Alpha-1 Product Portfolio
  60. 8.10.5 Kamada Ltd Recent Developments
  61. 8.11 Grifols
  62. 8.11.1 Grifols Company Information
  63. 8.11.2 Grifols Business Overview
  64. 8.11.3 Grifols Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Grifols Treatments for Alpha-1 Product Portfolio
  66. 8.11.5 Grifols Recent Developments
  67. 8.12 CSL Behring
  68. 8.12.1 CSL Behring Company Information
  69. 8.12.2 CSL Behring Business Overview
  70. 8.12.3 CSL Behring Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  71. 8.12.4 CSL Behring Treatments for Alpha-1 Product Portfolio
  72. 8.12.5 CSL Behring Recent Developments
  73. 8.13 Chiesi Pharmaceuticals
  74. 8.13.1 Chiesi Pharmaceuticals Company Information
  75. 8.13.2 Chiesi Pharmaceuticals Business Overview
  76. 8.13.3 Chiesi Pharmaceuticals Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Chiesi Pharmaceuticals Treatments for Alpha-1 Product Portfolio
  78. 8.13.5 Chiesi Pharmaceuticals Recent Developments
  79. 8.14 Boehringer Ingelheim
  80. 8.14.1 Boehringer Ingelheim Company Information
  81. 8.14.2 Boehringer Ingelheim Business Overview
  82. 8.14.3 Boehringer Ingelheim Treatments for Alpha-1 Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Boehringer Ingelheim Treatments for Alpha-1 Product Portfolio
  84. 8.14.5 Boehringer Ingelheim Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst